Skip to content

Ketamine research published in 2025

Page 14 of 39: studies 261 to 280 of 780, newest first. Back to the ketamine overview

Studies

Ketamine: farmacologia, indicações, diretrizes de dosagem e efeitos adversos

July 11, 2025 Sebastián Malleza

Após concluir esta atividade, os participantes deverão ser capazes de: Analisar os mecanismos farmacodinâmicos da cetamina, incluindo sua ação primária como antagonista do receptor NMDA e efeitos secundários sobre os receptores AMPA, sistemas opioides e vias de neuroplasticidade, a fim de otimizar a seleção do tratamento para pacientes com depressão resistente ao tratamento. Avaliar cenários...

Ketamine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

July 11, 2025 Sebastián Malleza

After completing this activity, participants should be able to: Analyze the pharmacodynamic mechanisms of ketamine, including its primary action as an NMDA receptor antagonist and secondary effects on AMPA receptors, opioid systems, and neuroplasticity pathways, to optimize treatment selection for patients with treatment-resistant depression. Evaluate clinical scenarios to determine when...

Ketamine-gids: farmacologie, indicaties, doseringsrichtlijnen en bijwerkingen

July 11, 2025 Sebastián Malleza

Na het voltooien van deze activiteit moeten deelnemers in staat zijn om: De farmacodynamische mechanismen van ketamine te analyseren, inclusief de primaire werking als NMDA-receptorantagonist en secundaire effecten op AMPA-receptoren, opioïde systemen en neuroplasticiteitspathways, om de behandelkeuze voor patiënten met therapieresistente depressie te optimaliseren. Klinische scenario's te...

The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment.

International Journal of Molecular Sciences July 11, 2025 Sofia Sakopoulos, Mcwelling Todman 6 citations

Ketamine infusion therapy has gained recognition as an innovative treatment for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects. Its therapeutic promise is increasingly understood to involve molecular and neurobiological processes that promote neural plasticity and cognitive flexibility. These changes may create a unique window for psychotherapeutic...

DOI: 10.3390/ijms26146673 (opens in new tab) Full text (opens in new tab) Ketamine infusion therapy Ketamine-assisted psychotherapy kap Rapid-acting antidepressant Treatment-resistant depression trd +2

Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.

Science Advances July 11, 2025 Lujuan He, Xuenan Wang, Shilin Luo et al. 8 citations

Arketamine, the (R)-enantiomer of (R,S)-ketamine, shows even greater rapid and sustained antidepressant-like effects in rodent models compared to esketamine, yet the underlying mechanisms remain unclear. In this study, we used the chronic social defeat stress (CSDS) model to investigate how arketamine exerts its antidepressant-like effects. We found that activating cAMP response element-binding...

[Subanesthetic Dose Ketamine Infusions for Treatment-Resistant Major Depression: An Application Protocol at a Public Hospital in Argentina].

Vertex Revista Argentina de Psiquiatría July 10, 2025 Micaela Dines, Adriana Bulacia, Paloma Bamondez et al.

Treatment-resistant major depression (TRD) poses a significant challenge in psychiatry due to the limited response to conventional therapies. Subanesthetic dose intravenous (IV) ketamine has emerged as an effective therapeutic option, providing rapid effects on depressive and suicidal symptoms. This article outlines the ketamine infusion protocol implemented in a general hospital, following...

When mood and time align: nasal esketamine reduces lived time disturbances in treatment-resistant depression.

International Journal of Psychiatry in Clinical Practice July 10, 2025 Stefan Jerotić, Milica Nestorovic, Janko Nešić et al. 3 citations

These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjective experience. Two male patients, aged 35 and 27, of Serbian ethnicity with treatment-resistant depression were treated with nasal esketamine, with clinical progress monitored using both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the...

In silico investigation of ketamine and methylphenidate drug-drug conjugate for MDD and ADHD treatment using MD simulations and MMGBSA

Scientific Reports July 8, 2025 Beenish Asrar, Nouman Ali, Imran Ali et al.

Major depressive disorder (MDD) and Attention-deficit hyperactivity disorder (ADHD) are pervasive psychiatric disorders characterized by impaired memory, sustained attention/motivation, and depression. FDA-approved Ketamine is an antidepressant drug but it affects cognitive abilities. Methylphenidate is the drug used for the treatment of ADHD. Chronic treatment overcomes attention and mental...

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.

Health policy (Amsterdam, Netherlands) July 8, 2025 Ramesh Joga, Sravani Yerram, Jayasri Devi Patnam et al. 5 citations

Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...

The parable of the TGA approval of esketamine (Spravato) in Australia: Part 2 - Submission for listing on the PBS.

Australasian Psychiatry July 8, 2025 William Lugg

ObjectivesTo review the available evidence, key deliberations, and potential influences behind the Pharmaceutical Benefits Advisory Committee's (PBAC's) conditional recommendation for esketamine to be listed on the Pharmaceutical Benefits Scheme (PBS).ConclusionsThis paper forms part 2 of the esketamine story in Australia-its handling by the Therapeutic Goods Administration (TGA) and,...

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.

Biochemical and Biophysical Research Communications July 8, 2025 Jiaxin Tian, Yanhong Xie, Sen Ye et al. 6 citations

The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...

DOI: 10.1016/j.bbrc.2025.151965 (opens in new tab) Full text (opens in new tab) S-ketamine Neuroinflammation Post-stroke depression psd Synaptic function +5

Primary Care Paramedic-administered Ketamine in British Columbia, Canada: A Patient Safety-focused Observational Study.

Journal of patient safety July 7, 2025 Tania Johnston, Christopher Mistiades, Roxane Beaumont-Boileau et al.

In Western Canada, British Columbia Emergency Health Services (BCEHS) aimed to enhance prehospital pain management by authorizing Primary Care Paramedics (PCP) to administer intranasal (IN) ketamine. The objective of this study is to describe patient safety implications of expanding PCP scope to include IN ketamine. This retrospective, observational study reviewed patient care records of the...

DOI: 10.1097/PTS.0000000000001390 (opens in new tab) Full text (opens in new tab) Medication safety Drug safety Patient safety Adverse event prevention +17

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.

Molecular Psychiatry July 7, 2025 Dongsun Park, Gwangho Lee, Won-Gyu Lee et al. 7 citations

Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting 5-HT2A receptors, both enhance...

Effects of ketamine on postoperative cognition: a scoping review.

British Journal of Anaesthesia July 7, 2025 Connor T A Brenna, Xuan W He, Daheng Liu et al. 8 citations

Postoperative delirium and other forms of perioperative neurocognitive deficits occur commonly in older adult patients. Ketamine, administered either before or during general anaesthesia, may have cognitive-sparing properties owing to its ability to reduce neuroinflammation, increase neurotrophin levels, or allow reductions in the doses of other general anaesthetic drugs. However, the efficacy...

DOI: 10.1016/j.bja.2025.05.035 (opens in new tab) Full text (opens in new tab) Arketamine Delayed neurocognitive recovery Perioperative neurocognitive disorders Postoperative delirium +3

Mu Opioid Receptor Activation is Required for NMDA Receptor Antagonist Effects on Stress-induced Maladaptive Behavior.

Biological Psychiatry July 7, 2025 Cory B Langreck, Briana K Chen, Victor M Luna et al. 9 citations

Contradictory evidence has emerged regarding the role of the mu opioid receptor (MOR) in the antidepressant actions of (R,S)-ketamine. Here, we used the long-acting MOR-selective antagonist methocinnamox (MCAM) to determine the contribution of MOR to the actions of (R,S)-ketamine and the more selective N-methyl-D-aspartate receptor (NMDAR) antagonist fluoroethylnormemantine (FENM) against...

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

The Journal of Clinical Psychiatry July 7, 2025 Angela T H Kwan, Moiz Lakhani, Joshua D. Rosenblat et al. 2 citations

Background: Ketamine and esketamine have been reported to rapidly alleviate various parameters of suicidality, with antisuicidal effects that may be independent of their rapid-acting antidepressant effects. However, it remains unclear whether ketamine and/or esketamine are associated with the emergence or worsening of suicidality. Methods: In this global observational pharmacovigilance cohort...

DOI: 10.4088/JCP.24m15534 (opens in new tab) Full text (opens in new tab) Esketamine Drug safety Medication safety Adverse drug events +11

Dose-dependent relationship between intra-operative ketamine administration and postoperative delirium: a retrospective cohort study.

Anaesthesia July 6, 2025 Lars Kaiser, Béla-Simon Paschold, Luca J Wachtendorf et al. 12 citations

Ketamine is used frequently as an adjunct for general anaesthesia, exerting analgesic and opioid-sparing properties at lower doses and psychotomimetic effects at higher doses. All dose ranges may have effects on the incidence of postoperative delirium, but clinical trials have been equivocal. We hypothesised that intra-operative low-dose ketamine is associated with a lower risk of postoperative...

DOI: 10.1111/anae.16681 (opens in new tab) Full text (opens in new tab) Multimodal anaesthesia Postoperative outcomes Postoperative delirium prevention Low-dose ketamine

Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East.

Journal of Psychoactive Drugs July 6, 2025 Khalid E Ahmed, Dima Abu Nasrieh, Haneen A Banihani et al. 1 citation

Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, and substance use disorders. However, perceptions of these treatments vary globally. This study explores the familiarity, attitudes, and perceptions of Jordanian physicians and medical students toward psychedelic substances, addressing a gap in Middle...

Comparison of the effects of esketamine/midazolam and remifentanil/midazolam on respiratory mechanics in mechanically ventilated patients with acute respiratory distress syndrome.

BMC Anesthesiology July 5, 2025 Dujuan Qiao, Wei Liu, Huanjia Xue et al. 5 citations

Esketamine exerts analgesic effects and has pharmacological properties of bronchodilation and elevation of mean arterial pressure, making it an interesting analgesic agent for patients with ARDS. Therefore, we conducted a randomized controlled trial comparing the effects of esketamine/midazolam and remifentanil/midazolam on respiratory mechanics and oxygenation in mechanically ventilated...